Readily Available Prognostic Biomarkers of Lung Cancer Treated With Immune Checkpoint Inhibitors in Northeast China.
PURPOSE There is a pressing clinical need for readily accessible markers to predict the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer treatment. In this study, we aimed to evaluate the prognostic value of common pre-treatment nutrition/inflammation-based indicators in lung cancer patients receiving pro...